用EXACT工具捕捉COPD急性加重:FLAME研究亚组分析
FLAME研究亚组457例患者使用EXACT问卷记录症状定义的急性加重,比较茚达特罗/格隆溴铵与沙美特罗/氟替卡松的效应,并评估症状定义事件与需医疗资源利用事件的一致性。结果显示症状定义加重年化率降低17%但无统计学意义,仅23.5%的症状事件对应医疗资源利用事件。
要点
- 茚达特罗/格隆溴铵较沙美特罗/氟替卡松非显著降低症状定义加重年化率17%。
- 症状定义加重与需医疗资源利用事件一致性低,κ指数仅0.24。
- 无论采用何种加重定义,结果均支持LABA/LAMA作为有加重风险患者的首选治疗。
核心结论
- 无论采用症状定义还是需医疗资源利用定义,茚达特罗/格隆溴铵均不劣于沙美特罗/氟替卡松,支持LABA/LAMA作为有未来加重风险COPD患者的首选治疗。
研究设计与样本
- FLAME研究亚组分析,纳入457例使用EXACT问卷记录症状定义加重的COPD患者。
- 所有患者使用电子日记记录症状恶化,需医疗资源利用的加重由研究者确认。
主要发现
- 茚达特罗/格隆溴铵较沙美特罗/氟替卡松的症状定义加重年化率比为0.83(95%CI 0.60-1.14,P=0.242),降低17%但无统计学意义。
- 首次症状定义加重时间风险比为0.76(95%CI 0.56-1.03,P=0.075),数值上更长但无统计学意义。
- 23.5%的症状定义事件对应需医疗资源利用事件,22.2%的需医疗资源利用事件被EXACT捕捉,κ指数0.24(95%CI 0.15-0.33)。
临床怎么用
- 临床中EXACT捕捉的症状加重与需就医的加重一致性低,仅约四分之一重叠,评估加重时需注意定义差异。
- 对于有加重风险的COPD患者,可优先选择LABA/LAMA(如茚达特罗/格隆溴铵)而非ICS/LABA。
局限性
- 为FLAME研究亚组分析,仅457例患者使用EXACT问卷,样本量有限。
- 症状定义加重与需医疗资源利用事件一致性低,可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Chronic obstructive pulmonary disease exacerbations accelerate lung function decline, reduce quality of life, and increase mortality. A subset of patients (n = 457) from the FLAME (Effect of Indacaterol Glycopyrronium vs. Fluticasone Salmeterol on COPD Exacerbations) study used the Exacerbations of COPD Tool (EXACT) to capture symptom-defined exacerbations. OBJECTIVES: To evaluate the effect of indacaterol/glycopyrronium versus salmeterol/fluticasone on symptom-defined exacerbations measured using EXACT, and to assess differences between these events and exacerbations requiring healthcare resource use (HCRU). METHODS: All patients in FLAME used an electronic diary to record and detect symptom deteriorations; HCRU-related exacerbations were confirmed by investigators. In patients using the EXACT questionnaire, the onset, recovery, and magnitude of symptom-defined exacerbations were identified by changes in total scores relative to baseline. We analyzed the annualized rate and time to first symptom-defined (EXACT) exacerbation and assessed differences between symptom-defined and HCRU events in terms of number, severity, and concordance. MEASUREMENTS AND MAIN RESULTS: A nonsignificant 17% reduction in the annualized rate of symptom-defined (EXACT) exacerbations (rate ratio, 0.83; 95% confidence interval [CI], 0.60-1.14; P = 0.242) and a numerically longer time to first symptom-defined exacerbation were observed with indacaterol/glycopyrronium versus salmeterol/fluticasone (hazard ratio, 0.76; 95% CI, 0.56-1.03; P = 0.075). These results were consistent with data from the overall FLAME population. Of the symptom-defined (EXACT) events, 23.5% corresponded to HCRU events, and 22.2% of HRCU events were captured by EXACT (κ index, 0.24; 95% CI, 0.15-0.33). CONCLUSIONS: Regardless of the exacerbation definition used, our findings support the use of long-acting β2 agonists/long-acting muscarinic receptor antagonists as the preferred treatment option for patients at risk of future exacerbations. Clinical trial registered with www.clinicaltrials.gov (NCT01782326).
引用
- Frent SM, Chapman KR, Larbig M, et al. Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME. Am J Respir Crit Care Med. 2019. PMID: 30019939. doi:10.1164/rccm.201801-0038OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。